Skip to main content
. 2022 Jul 11;55(1):141–150. doi: 10.1007/s11255-022-03287-1

Table 3.

Changes in iron-related parameters and in mineral and bone disorder-related parameters in patients from the GBA4-6 study undergoing hemodialysis

Mean (SD) With GASI, n = 95 Without GASI, n = 85
BL EOT Change BL EOT Change
Serum iron [µg/dL]

61.5

(21.0)

85.5

(35.9)

24.0

(39.6)

58.5

(20.5)

84.2

(38.3)

25.6

(40.2)

Serum ferritin [ng/mL]

79.51

(73.10)

245.83

(165.33)

166.32

(153.70)

92.52

(88.95)

247.69

(174.60)

155.16

(139.47)

TIBC [µg/dL]

250.8

(44.6)

211.3

(34.6)

 − 39.5

(35.0)

255.2

(43.6)

215.1

(32.2)

 − 40.1

(31.3)

TSAT [%]

24.94

(8.50)

41.54

(18.57)

16.60

(19.44)

23.30

(8.38)

39.32

(17.34)

16.02

(18.81)

Hb [g/dL]

10.89

(1.00)

11.13

(1.26)

0.24

(1.43)

11.06

(1.07)

11.28

(1.26)

0.23

(1.18)

Serum P [mg/dL]

5.46

(1.13)

5.23

(1.07)

 − 0.23

(1.41)

5.61

(1.36)

5.64

(1.53)

0.02

(1.69)

Serum cCa [mg/dL]

9.21

(0.59)

9.07

(0.63)

 − 0.14

(0.56)

9.17

(0.55)

8.86

(0.58)

 − 0.30

(0.57)

iPTH [pg/mL]

151.9

(107.0)

208.3

(130.8)

56.3

(119.0)

165.0

(144.6)

227.1

(144.5)

62.1

(129.0)

Ca*P [(mg/dL)2]

50.26

(10.66)

47.51

(10.43)

 − 2.75

(13.07)

51.45

(12.72)

49.84

(13.42)

 − 1.60

(14.84)

BL baseline, Ca*P calcium–phosphate product, cCa corrected calcium, EOT end of treatment, GASI gastric acid secretion inhibitor, Hb hemoglobin, iPTH intact parathyroid hormone, P phosphate, SD standard deviation, TIBC total iron-binding capacity, TSAT transferrin saturation